Your browser doesn't support javascript.
loading
Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review.
Schijman, Alejandro Gabriel; Alonso-Padilla, Julio; Britto, Constança; Herrera Bernal, Claudia Patricia.
Afiliação
  • Schijman AG; Laboratorio de Biología Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr Héctor Torres", INGEBI- CONICET, Vuelta de Obligado 2490, Buenos Aires, 1428 ADN, Argentina.
  • Alonso-Padilla J; Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Carrer Rosselló 149, 08036, Barcelona, Spain.
  • Britto C; CIBER de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
  • Herrera Bernal CP; Fundação Oswaldo Cruz, Fiocruz, Instituto Oswaldo Cruz, Laboratory of Molecular Biology and Endemic Diseases, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, 21045-900, Brazil.
Lancet Reg Health Am ; 36: 100821, 2024 Aug.
Article em En | MEDLINE | ID: mdl-39006126
ABSTRACT
Chagas disease, caused by Trypanosoma cruzi, affects millions worldwide. The 2030 WHO roadmap aims to eliminate it as a public health concern, emphasising the need for timely diagnosis to enhance treatment access. Current diagnostic algorithms, which rely on multiple tests, have prolonged turnaround times. This proves particularly problematic in resource-limited settings. Addressing this issue necessitates the validation and adoption of innovative tools. We explore recent developments in Chagas disease diagnosis, reviewing historical context and advancements. Despite progress, challenges persist. This article contributes to the understanding of current and future directions in this neglected healthcare area. Parasitological methods are simple but exhibit low sensitivity and require supplementary tests. Molecular methods, with automation potential, allow quantification and higher throughput. Serological tools show good performance but struggle with parasite antigenic diversity. Prioritising point-of-care tests is crucial for widespread accessibility and could offer a strategy to control disease impact. Ultimately, balancing achievements and ongoing obstacles is essential for comprehensive progress.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Lancet Reg Health Am Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Argentina

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Lancet Reg Health Am Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Argentina